All the top Biotech & Pharma news in one daily newsletter.

What to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 900+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Approvals & Labels

Bristol Myers Squibb’s Cobenfy approval by the FDA ushers in the first new schizophrenia drug in more than two decades
Small molecule, schizophrenia - Read more

AstraZeneca scores FDA ok for expanded Tagrisso label
Small molecule, lung cancer - Read more

THE GOOD
Business Development

CSL Seqirus lands 5th avian flu pademic preparedness contract from BARDA, $121.4M
Vaccine, bird flu (avian flu), pandemic preparedness - Read more

Repair Technologies in-licenses Genevant’s LNP tech for $107M total upfront + biobucks
mRNA, lipid nanoparticle (LNP), atherosclerosis, cholesterol - Read more

Merck & Co. signs options and licensing deal with Evaxion Biotech for their preclinical gonorrhoea, infectious disease vaccines, up to $592M biobucks per asset
Vaccine, gonorrhoea, infectious disease - Read more

THE GOOD
Clinical Trials

Genentech (Roche) posts positive Ph3 for lupus med Gazyva
Monoclonal antibody, lupus nephritis - Read more

enGene posts promising first set of Ph3 data for detalimogene in bladder cancer
Non-viral gene therapy, bladder cancer - Read more

AbbVie’s tavapadon scores second Ph3 victory in Parkinson’s disease
Small molecule, Parkinson’s disease - Read more

AbbVie touts positive ad-hoc Ph3 analysis data for Rinvoq in atopic dermatitis
Small molecule, atopic dermatitis - Read more

Enanta Pharmaceuticals’ RSV antiviral EDP-323 meets Ph2a challenge
Small molecule, respiratory syncytial virus, antiviral - Read more

UNION Therapeutics showcases promising Ph2b data for orismilast in atopic dermatitis
Small molecule, atopic dermatitis - Read more

Biomea Fusion’s BMF-219 clinical hold lifted by FDA
Small molecule, type 2 diabetes, type 1 diabetes - Read more

THE GOOD
Company Launches

Mirai Bio is Flagship Pioneering’s newest endeavour, looking to solve key drug delivery challenges for genetic medicines
Cell & gene therapy, drug delivery, AI - Read more

PRESENTED BY YOU?
Get 900+ sets of biotech/pharma eyeballs on your product or service 👀

Looking to promote your biotech/pharma/life science-focused product or service to a captivated audience of industry professionals?

Consider sponsoring TLDR Biotech - your sponsored feature would go right here!

Ready to make a deal (or want more info)? Just reply to this email or message me on LinkedIn.

⬇️ The Good News (Cont’d) ⬇️

THE GOOD
Fundraises

ARCH Venture Partners announces a cool $3B for their 13th fund
Venture capital, biotech investment - Read more

Asabys Partners closes new €180M ($201M) fund
Venture capital, biotech investment - Read more

858 Therapeutics $50M Series B
Small molecule, solid tumor - Read more

ReSync Bio undisclosed raise
Scientific software, drug discovery - Read more

Eradivir closes $10.25M Series A
Small molecule bispecific antibody fusion, influenza, infectious disease - Read more

THE GOOD
Mergers & Acquisitions

Dotmatics acquires Virscidian
Scientific software, laboratory workflow automation, R&D workflows - Read more

Undisclosed PE firm makes $16B+ bid for Sanofi’s consumer health business
Consumer health, corporate spin-out - Read more

THE GOOD
Partnerships

Novo Nordisk, Evotec partner on developing off-the-shelf, stem-cell based cell therapies
Cell therapy, drug development, Parkinson’s disease, diabetes - Read more

AstraZeneca, Immunai expand AI-powered oncology drug development partnership
Antibody, oncology, drug development - Read more

Lundbeck, Iambic Therapeutics partner on AI-powered drug discovery
Small molecule, migraine, drug discovery - Read more

Biocon, Tabuk Pharmaceuticals partner on commercializing GLP-1 products in the Middle East
GLP-1, obesity, diabetes - Read more

ENJOYING THESE NEWSLETTERS?
Support TLDR Biotech🧬🦠🔬 

I’m offering this newsletter for free so it can get out to as many people as possible.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.*

*Best of all, it’s a work-related news source that you can likely expense. 😉 

THE BAD
Earnings & Finances

Inventiva struggles to stay afloat as cash runway extends to mid-October 2024
Small molecule, metabolic dysfunction-associated steatohepatitis, non-alcoholic steatohepatitis - Read more

THE BAD
IPOs

Better luck next year? Insilico Medicine’s Hong Kong IPO ambitions look to be naught
AI-enabled drug discovery - Read more [Paywall]

THE BAD
Partnerships

Biogen discontinues Sage Therapeutics SAGE-324 partnership after disappointing Ph2 data earlier this year
Small molecule, essential tremor - Read more

THE BAD
Regulatory

FDA’s oncology adcomm favours narrowing PD-1 inhibitor approvals in 10-2 vote; Bristol Myer Squibb’s Opdivo, Merck & Co.’s Keytruda and BeiGene’s Tevimbra in the crosshairs
Monoclonal antibody, stomach cancer - Read more

THE BAD
Research

Retrospective study indicates “[no] significantly slower progression of disability“ for MS patients using Roche’s Ocrevus or Roche & Biogen’s Rituxan
Monoclonal antibody, multiple sclerosis - Read more

THE UGLY
Criminal Acts

NIH neuroscience top dog whose work underpins several Parkinson’s and Alzheimer’s clinical assets committed alleged widespread research misconduct, according to NIH investigation
Academic misconduct, Parkinson’s, Alzheimer’s - Read more

THE UGLY
Marketing

Novo Nordisk draws UK’s PMCPA ire over alleged Saxenda (older GLP-1 drug) and pharmacy chain promotion
GLP-1, drug marketing - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here